In clinical trials
Digestive & weight
Retatrutide
Evidence
Phase 3 trials underway
Class
GIP, GLP-1 and glucagon receptor agonist
KEY TAKEAWAY
Retatrutide is an investigational peptide that acts on three receptors: GIP, GLP-1 and glucagon. In a phase 2 trial, adults with obesity lost up to about 24% of their body weight over 48 weeks. It is not approved and larger trials are still running.
Written by the Veylo editorial team · Updated
November 2026
What it is
An investigational triple-hormone receptor agonist
Studied for
Obesity and type 2 diabetes, in phase 3 trials
Key fact
Up to about 24% weight loss at 48 weeks in a phase 2 trial
Route
Weekly injection (investigational)
Evidence strength
Phase 3 trials underway
Retatrutide is a once-weekly injectable peptide in development. It targets GIP, GLP-1 and glucagon receptors together.
The GIP and GLP-1 actions reduce appetite and improve blood sugar. Glucagon receptor activity may add to energy use and fat metabolism in the liver.
Retatrutide has not been approved by the FDA or any other major regulator. It is in late-stage clinical trials. Products sold online as retatrutide are not approved medicines.
Investigated for obesity, type 2 diabetes and fatty liver disease. Use outside a clinical trial is not supported by approved labeling.
Nausea, diarrhea, vomiting and constipation were common in trials. Heart rate increases were seen in a dose-dependent way, and some people reported altered skin sensation. Long-term safety is not yet known.
Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity. N Engl J Med. 2023;389:514-526.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.